Artificial intelligence (AI) is poised to transform therapeutic science. Therapeutics Data Commons is an initiative to access and evaluate AI capability across therapeutic modalities and stages of discovery, establishing a foundation for understanding which AI methods are most suitable and why.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
DCGAN-DTA: Predicting drug-target binding affinity with deep convolutional generative adversarial networks
BMC Genomics Open Access 09 May 2024
-
Building trust in deep learning-based immune response predictors with interpretable explanations
Communications Biology Open Access 06 March 2024
-
A knowledge-guided pre-training framework for improving molecular representation learning
Nature Communications Open Access 21 November 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Pushpakom, S. et al. Nat. Rev. Drug Discovery 18, 41–58 (2019).
Macarron, R. et al. Nat. Rev. Drug Discovery 10, 188–195 (2011).
Gao, W., Raghavan, P. & Coley, C. W. Nat. Commun. 13, 1–4 (2022).
LeCun, Y., Bengio, Y. & Hinton, G. Nature 521, 436–444 (2015).
Vamathevan, J. et al. Nat. Rev. Drug Discovery 18, 463–477 (2019).
Stokes, J. M. et al. Cell 180, 688–702 (2020).
Gysi, D. M. et al. Proc. Natl Acad. Sci. USA 118, e2025581118 (2021).
Jumper, J. et al. Nature 596, 583–589 (2021).
Schneider, P. et al. Nat. Rev. Drug Discov. 19, 353–364 (2020).
Wilkinson, M. D. et al. Sci. Data 3, 1–9 (2016).
Chandrasekaran, S. N., Ceulemans, H., Boyd, J. D. & Carpenter, A. E. Nat. Rev. Drug Discov. 20, 145–159 (2021).
Sanchez-Lengeling, B. & Aspuru-Guzik, A. Science 361, 360–365 (2018).
Walters, W. P. & Murcko, M. Nat. Biotechnol. 38, 143–145 (2020).
Brown, N., Fiscato, M., Segler, M. H. & Vaucher, A. C. J. Chem. Inf. Model. 59, 1096–1108 (2019).
Gao, W. & Coley, C. W. J. Chem. Inf. Model. 60, 5714–5723 (2020).
Graff, D. E., Shakhnovich, E. I. & Coley, C. W. Chem. Sci. 12, 7866–7881 (2021).
Zhavoronkov, A. et al. Nat. Biotechnol. 37, 1038–1040 (2019).
Townshend, R. J. et al. Science 373, 1047–1051 (2021).
Hodgson, J. Nat. Biotechnol. 19, 722–726 (2001).
Zagidullin, B. et al. Nucleic Acids Res 47, W43–W51 (2019).
Öztürk, H., Özgür, A. & Ozkirimli, E. Bioinformatics 34, i821–i829 (2018).
Huang, K. et al. Preprint at https://doi.org/10.48550/arXiv.2010.03951 (2020).
Urbina, F., Lentzos, F., Invernizzi, C. & Ekins, S. Nat. Mach. Intell. 4, 189–191 (2022).
Gilmer, J., Schoenholz, S. S., Riley, P. F., Vinyals, O. & Dahl, G. E. In Proc. 34th International Conference on Machine Learning (eds Precup, D. & Teh, Y. W.) 70, 1263–1272 (2017).
Xie, Y. et al. In Proc. 9th International Conference on Learning Representations (Spotlight Proceedings) https://openreview.net/forum?id=kHSu4ebxFXY (2021).
Acknowledgements
K.H. and M.Z. gratefully acknowledge the support of US National Science Foundation (NSF) awards IIS-2030459 and IIS-2033384, US Air Force contract no. FA8702-15-D-0001 and awards from the Harvard Data Science Initiative, Amazon Research, Bayer Early Excellence in Science, AstraZeneca Research and the Roche Alliance with Distinguished Scientists. W.G. was supported by the US Office of Naval Research under grant no. N00014-21-1-2195. C.W.C. was supported by the Machine Learning for Pharmaceutical Discovery and Synthesis (MLPDS) Consortium. J.S. was supported by NSF awards SCH-2014438, IIS-1838042, US National Institutes of Health (NIH) award 1R01NS107291-01, and OSF Healthcare. J.L. was supported by the US Defense Advanced Research Progress Agency under awards HR00112190039, N660011924033; the Army Research Organization under nos. W911NF-16-1-0342, W911NF-16-1-0171; the NSF under nos. OAC-1835598, OAC-1934578, CCF-1918940; the NIH under no. 3U54HG010426-04S1; and the Stanford Data Science Initiative, the Wu Tsai Neurosciences Institute, Amazon, Docomo, GSK, Hitachi, Intel, JPMorgan Chase, Juniper Networks, KDDI, NEC and Toshiba. Any opinions, findings, conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the funders.
Author information
Authors and Affiliations
Contributions
K.H., T.F., W.G. and M.Z. designed the data management and computational infrastructure. K.H., T.F., W.H., Y.Z., Y.R. and M.Z. implemented the programming interface and software package. K.H., T.F., W.H. and Y.R. retrieved, processed and harmonized datasets. K.H. and M.Z. designed and implemented the website. K.H., T.F., W.H., Y.Z., Y.R., J.L., C.C, C.X., J.S. and M.Z. wrote and edited the manuscript. M.Z. conceived and supervised the study.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Huang, K., Fu, T., Gao, W. et al. Artificial intelligence foundation for therapeutic science. Nat Chem Biol 18, 1033–1036 (2022). https://doi.org/10.1038/s41589-022-01131-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41589-022-01131-2
This article is cited by
-
DCGAN-DTA: Predicting drug-target binding affinity with deep convolutional generative adversarial networks
BMC Genomics (2024)
-
Building trust in deep learning-based immune response predictors with interpretable explanations
Communications Biology (2024)
-
Application of variational graph encoders as an effective generalist algorithm in computer-aided drug design
Nature Machine Intelligence (2023)
-
A knowledge-guided pre-training framework for improving molecular representation learning
Nature Communications (2023)
-
Evaluating explainability for graph neural networks
Scientific Data (2023)